The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia (CLL)

Thorsten Zenz,[1] Sonja Häbe,[1] Axel Benner,[2] Dirk Kienle,[1] Hartmut Döhner[1] and Stephan Stilgenbauer[1]
[1]Department of Internal Medicine III, University of Ulm, Ulm, Germany; [2]Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany

Citation: Zenz T, Häbe S, Benner A, Kienle D, Döhner H, Stilgenbauer S. The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica 2008 doi: 10.3324/haematol.12738



Supplementary Figure S1. DHPLC pattern of single (A) and multiple (normalized graph) (B) samples with different MDM2 309 SNP sequences. The lower part of the figure (C) shows the respective sequences.

A



B



Supplementary Figure S2. (A) Quantitative gene expression and MDM2-SNP309: mRNA levels of MDM2 and P53 stratified by genotype. (B) MDM2-SNP309 has no influence on overall survival in CLL: Kaplan-Meier blot for overall survival in a cohort of patients with CLL (p=0.96).